雙成藥業(002693.SZ):預計2021年度淨虧損1200萬元–1800萬元
格隆匯1月17日丨雙成藥業(002693.SZ)公佈公司2021年度業績預吿,公司預計2021年度公司歸屬於上市公司股東的淨利潤為虧損1200萬元–1800萬元;扣除非經常性損益後的淨利潤為虧損3088萬元-3688萬元;基本每股虧損0.03元/股–0.04元/股。
預計報吿期公司經營業績較上年同期有所提升,影響業績變動的主要原因:
(1)公司加強市場產品銷售,是在境內銷量穩步增長同時,積極拓展國際市場,出口銷售有所增幅、受託研發業務也穩步擴展,使得營業收入及利潤有所上升;
(2)報吿期內,公司取得依替巴肽注射液藥品批准文號及註冊批准文件,確認產品權利轉讓收益,使得利潤增加約人民幣1,376萬元;
(3)上年同期控股子公司寧波雙成藥業有限公司針對部分固定資產計提減值約人民幣938萬元,報吿期無此類業務;
預計報吿期內非經常性損益對淨利潤的貢獻金額約為人民幣1888萬元左右,主要系依替巴肽注射液產品權利轉讓收益、按期攤銷進入損益的政府補助收入及理財收益等所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.